COMMUNIQUÉS West-GlobeNewswire

argenx announces results of Annual General Meeting of Shareholders

07/05/2024 - 23:30

May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced [...]

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/05/2024 - 22:38

BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting [...]

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

07/05/2024 - 22:30

REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

07/05/2024 - 22:30

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pietrusko, PharmD to [...]

DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités

07/05/2024 - 22:30

Montrouge, France, le 7 mai DBV Technologies publie ses résultats financiers du premier trimestre 2024 et fait le point sur ses activités Recrutement de VITESSE en bonne voie pour l’inclusion du dernier patient au [...]

Lifeward to Report First Quarter Financial Results on May 15, 2024

07/05/2024 - 22:30

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing [...]

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

07/05/2024 - 22:30

NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and [...]

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

07/05/2024 - 22:19

Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen ® and other injectors used for the treatment of anaphylaxis On track to complete [...]

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

07/05/2024 - 22:15

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial [...]

Certara Reports First Quarter 2024 Financial Results

07/05/2024 - 22:15

Reiterates Full Year 2024 Financial Guidance PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter [...]

Globus Medical Reports First Quarter 2024 Results

07/05/2024 - 22:15

AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net [...]

Spectral AI Announces 2024 First Quarter Financial Results

07/05/2024 - 22:15

Q1 Overview Research & Development Revenue of $6.3 Million Improved Capital Structure Reflected in Cash of $10.2 Million DeepView AI ® -Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024 Additional [...]

Merus annonce l’acceptation par la FDA américaine et l’examen prioritaire de la demande de licence de produit biologique relative à Zeno dans le traitement du CPNPC et de l’ACP NRG1+

07/05/2024 - 22:12

S’il est approuvé, Zeno sera le premier traitement ciblé pour le cancer NRG1+ UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 07 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : Merus (Merus, la Société, nous ou notre/ [...]

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

07/05/2024 - 22:05

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]

Avid Bioservices to Participate at Upcoming Investor Conferences

07/05/2024 - 22:05

TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high [...]

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

07/05/2024 - 22:05

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 7, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling [...]

Oculis Publishes Invitation to the Annual General Meeting

07/05/2024 - 22:05

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen- [...]

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

07/05/2024 - 22:05

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and [...]

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

07/05/2024 - 22:05

FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]